Press

Israeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound

Jan 31 • 3 min read

Clearmind Medicine Inc. (NASDAQ: CMND | CSE: CMND | FSE: CWY), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that as part of its ongoing collaboration with the Bar-Ilan University, Israel and Professor Gal Yadid, from the Gonda Multidisciplinary Brain Research Center, a…

BetterLife Announces Engagement of Bloom Burton Securities Inc. and Provides Summary of 2022 Accomplishments

Jan 30 • 5 min read

BetterLife Pharma Inc (CSE: BETR | OTCQB: BETRF | FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce the engagement of Bloom Burton Securities Inc. (“Bloom Burton”) for strategic advisory services to support BetterLife’s growth and development initiatives towards clinical trials. “We are very excited to be working…

FSD Pharma Inc. Commences Recruitment in FSD201 Phase 2 Clinical Trial

Jan 30 • 2 min read

FSD Pharma (NASDAQ: HUGE | CSE: HUGE | FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide. The company today announced that recruiting is underway for its phase 2 trial of FSD201 for the treatment of chronic pain associated with idiopathic MCAS…

Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Jan 30 • 2 min read

Bright Minds Biosciences Inc. (CSE:DRUG | NASDAQ:DRUG) announces that it has received a notification letter from the Nasdaq Stock Market LLC dated January 26, 2023, notifying the Company that due to thirty consecutive business days of closing bid prices for the common shares in the capital of the Company being below US$1.00 per Share, Bright…

Irwin Naturals Signs Letter of Intent to Acquire Braxia Scientific

Jan 30 • 7 min read

Irwin Naturals Inc. (CSE: IWIN | OTC: IWINF | FRA: 97X), is pleased to announce it has entered into a non-binding amended and restated Letter of Intent (“LOI”) for a business combination with Braxia Scientific Corp., (CSE: BRAX | OTC: BRAXF | FWB: 4960), a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427